Pilot project aims to cut out spread of HIV

It’s not quite the HIV morning after pill, but a new pilot project in Vancouver hopes to help cut off the spread of the virus after high-risk exposures.

The Non-occupational Post-Exposure Prophylaxis (NPEP) project was launched Monday by the B.C. Centre for Excellence in HIV/AIDS.

For the next 18-months, people who have had a high-risk exposure to HIV/AIDS – whether through sexual contact or by sharing needles – will be able to access highly active antiretroviral therapy (HAART), which is typically used to substantially reduce the viral load in HIV-positive patients.

According to Dr. Val Montessori, people who start HAART treatment within 72 hours of being exposed to HIV are 80 per cent less likely to become infected by the virus.

“Time really is of the essence,” said Montessori. “They can just walk in [to St. Paul’s Hospital] and the staff is ready to go. After 72 hours, the effectiveness falls off quickly.”

Read More

Scroll to Top

During the Canada Post strike announced September 25, 2025, the following measures will be undertaken to minimize service disruption to BC-CfE clients and providers.

  • The BC-CfE Laboratory has transitioned to private courier for delivery of outgoing reports and documents. Results required urgently can be faxed upon request. (Lab Contact Information: Phone 604-806-8775; FAX 604-806-9463)
  • The BC-CfE Drug Treatment Program (DTP) will fax outgoing forms and documents to the provider’s office. (DTP Contact Information: Phone 604-806-8515; FAX 604-806-9044)
  • St. Paul’s Hospital Ambulatory Pharmacy has transitioned to private courier for delivery of medications. We recommend requesting medication at least 2 weeks in advance in case of delivery delays, particularly to rural/remote parts of BC. (Contact Information: Phone 1-800-547-3622; FAX 604-806-8675)

During the Canada Post strike, we recommend that documents be faxed or couriered to our sites, versus utilization of regular mail service

The BC-CfE Laboratory is streamlining reporting processes for certain tests in order to simplify distribution and record-keeping, and to ensure completeness of results. Beginning September 2, 2025, results for the ‘Resistance Analysis of HIV-1 Protease and Reverse Transcriptase’ (Protease-RT) and ‘HIV-1 Integrase Resistance Genotype’ tests will be combined into a single ‘HIV-1 Resistance Genotype Report’.
For more details and example reports, please click on the button below